Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

6 Jun 2014

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to HER2/EGFR in Cancer Research
Share to Lymphoma Diagnosis and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 24903481
DOI: 10.1038/leu.2014.184

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphomaPMID 24903481Read ↗

MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.Semantic proximity Read ↗

Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients.Semantic proximity Read ↗

Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.Semantic proximity Read ↗

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.Semantic proximity Read ↗

Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma.Semantic proximity Read ↗

MYD88 gene and protein: molecular architecture, signalling mechanisms and clinical implications in lymphoid malignancies.Semantic proximity Read ↗

Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.Semantic proximity Read ↗

MYD88 <sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapySemantic proximity Read ↗

MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma.Semantic proximity Read ↗

MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell LymphomaSemantic proximity Read ↗

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.